Form 4: Guardant Health CIO's Routine Stock Transactions

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and subsequent share transactions, including tax-related dispositions.

Summary

• Kumud Kalia, Chief Information Officer of Guardant Health, Inc., reported transactions involving common stock and restricted stock units (RSUs).
• On September 15, 2025, 638 shares of common stock were acquired upon the vesting of RSUs.
• Concurrently, 324 shares of common stock were disposed of at a price of $54.79 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Kalia beneficially owns 19,164 shares of common stock and 1,912 derivative securities (RSUs).
• The reported RSU award was granted on June 9, 2023, with 33% vesting on June 15, 2024, and the remaining 67% vesting in equal quarterly installments over the subsequent two years.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to executive compensation, which is a neutral to slightly positive event as it indicates continued alignment of management interests. There are no unexpected positive or negative disclosures.

Positives

• Vesting of 638 restricted stock units indicates continued compensation and alignment of management interests with shareholders.
• The RSU award structure, vesting over three years, suggests a long-term retention strategy for key personnel.

Negatives

• Disposition of 324 shares for tax withholding reduces the direct beneficial ownership of common stock by the insider.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

The filing indicates future vesting events for the remaining 67% of the RSU award in equal quarterly installments over a two-year period following June 15, 2024.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide broader industry context or trends. It reflects standard compensation practices for executives in publicly traded companies, particularly in the biotechnology or healthcare technology sector where Guardant Health operates.

Comparison to Industry Standards

• This filing details a standard RSU vesting and tax withholding transaction, which is a common practice for executive compensation across various industries.
• No specific comparable companies or projects are mentioned in the filing to allow for a detailed comparison.

Stakeholder Impact

• Shareholders: Minor impact, as it reflects a routine change in insider ownership and compensation. It signals continued executive commitment through equity incentives.
• Employees: No direct impact on general employees.
• Management: The vesting and subsequent transactions are part of the Chief Information Officer's compensation package, aligning their interests with company performance.

Next Steps

• Future quarterly vesting installments of the remaining 67% of the RSU award over the two-year period following June 15, 2024.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax withholding). It does not contain information significant enough to warrant a 'buy' or 'sell' recommendation, nor does it provide new strategic or financial data that would materially alter the investment thesis for Guardant Health. It simply confirms ongoing executive equity incentives.

Keywords

Guardant Health, GH, Kumud Kalia, Chief Information Officer, CIO, Form 4, insider trading, stock transactions, restricted stock units, RSU vesting, beneficial ownership, tax withholding